Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

The 2016 revision of the World Health Organization classification of tumors of hematopoietic
and lymphoid tissues is characterized by a closer integration of morphology and molecular …

An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and …

The International Prognostic Scoring Sytem (IPSS) is an important standard for ssessing
prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML)
that is used for prognostic, predictive, monitoring, and efficacy-response assessments. …

Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), …

Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell
transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small …

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1 , 2 . In patients with
myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease …

Mesenchymal niche cells may drive tissue failure and malignant transformation in the
hematopoietic system, but the underlying molecular mechanisms and relevance to human disease …

Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and
prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and …